Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

The Effect of Information Support Program on Self-efficacy of Prostate Cancer Patients During Hormonal Therapy

Not Applicable

Completed

Conditions: Information Support

Interventions: Other: information support program

First Posted Date: 2020-04-09

Last Posted Date: 2020-04-09

Lead Sponsor: Fudan University

Target Recruit Count: 95

Registration Number: NCT04340713

Locations: 🇨🇳
Rui Yang, Shanghai, China

Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Device: cryo-ablation

First Posted Date: 2020-04-06

Last Posted Date: 2020-04-06

Lead Sponsor: Fudan University

Target Recruit Count: 186

Registration Number: NCT04334785

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Lateral Neck Lymph Node Mapping in Thyroid Cancer

Not Applicable

Conditions: Thyroid Cancer

Interventions: Procedure: Modified lateral neck lymph node dissection
Procedure: Lateral neck sentinel lymph node biopsy
Procedure: Super selective lateral neck lymph node dissection

First Posted Date: 2020-03-18

Last Posted Date: 2020-03-18

Lead Sponsor: Fudan University

Target Recruit Count: 250

Registration Number: NCT04312087

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

Phase 2

Conditions: Thyroid Cancer

Interventions: Drug: Anlotinib
Procedure: surgery
Procedure: core needle biopsy

First Posted Date: 2020-03-16

Last Posted Date: 2021-04-01

Lead Sponsor: Fudan University

Target Recruit Count: 13

Registration Number: NCT04309136

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

Phase 3

Conditions: Breast Cancer

Interventions: Drug: Capecitabine
Drug: Vinorelbine

First Posted Date: 2020-03-13

Last Posted Date: 2020-03-13

Lead Sponsor: Fudan University

Target Recruit Count: 316

Registration Number: NCT04307147

Locations: 🇨🇳
Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: SHR-1316
Drug: Bevacizumab
Drug: Cisplatin/Carboplatin

First Posted Date: 2020-03-11

Last Posted Date: 2024-07-18

Lead Sponsor: Fudan University

Target Recruit Count: 35

Registration Number: NCT04303988

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Vinorelbine
Drug: Capecitabine

First Posted Date: 2020-03-10

Last Posted Date: 2020-03-10

Lead Sponsor: Fudan University

Target Recruit Count: 550

Registration Number: NCT04302441

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma

Phase 2

Recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Camrelizumab
Combination Product: US/CT-guided Percutaneous Cryoablation

First Posted Date: 2020-03-09

Last Posted Date: 2023-09-13

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT04299581

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

Phase 3

Recruiting

Conditions: Triple-negative Breast Cancer

Interventions: Drug: ddEpirubicin
Drug: Epirubicin
Drug: CTX
Drug: ddCTX
Drug: Paclitaxel(with carbo)
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2020-03-05

Last Posted Date: 2023-11-14

Lead Sponsor: Fudan University

Target Recruit Count: 808

Registration Number: NCT04296175

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Vinorelbine
Drug: Capecitabine
Drug: Trastuzumab

First Posted Date: 2020-03-05

Last Posted Date: 2020-03-05

Lead Sponsor: Fudan University

Target Recruit Count: 178

Registration Number: NCT04296162

Locations: 🇨🇳
Zhi-Ming Shao, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy